Abbisko Therapeutics Co, Ltd
Quick facts
Phase 3 pipeline
- Pimicotinib(ABSK021) · Oncology
Pimicotinib is a tyrosine kinase inhibitor that targets HER2 (human epidermal growth factor receptor 2) to inhibit cancer cell growth and proliferation.
Phase 2 pipeline
- ABSK-011
- ABSK021 · Oncology
ABSK021 is a small molecule targeting the PI3K/AKT/mTOR pathway. - ABSK043 in combination with Firmonertinib
- ABSK043 in combination with Glecirasib
Phase 1 pipeline
- [14C]ABSK011
- ABSK021 with fasted state
- ABSK021 with fed state
- ABSK043 oral capsule
- ABSK061
- ABSK091 tablet
- ABSK112
- ABSK121-NX
- ABSK131
- Part A ABSK201 and Itraconazole
- Part A ABSK201 and Rifampicin
- Pimicotinib capsule
- pimicotinib capsules
- Sequence A ABSK-011
- Sequence B ABSK-011
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: